GlassScriptPhysician profile
Joshua Grube
NPI 1669852984
$5,027.21
in general payments reported to CMS, 2019-2025
31 companies · $907 in 2025
The $907 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $138 · 2021: $626 · 2022: $869 · 2023: $1,045 · 2024: $1,061 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,012.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $773.69 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $604.60 | 2019-2025 | |
| Abbvie INC. | $585.18 | 2019-2025 | |
| Glaxosmithkline, LLC. | $551.66 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $374.18 | 2019-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $245.46 | 2020-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $227.56 | 2022-2025 | |
| Renalytix Ai, INC. | $202.77 | 2023-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Phathom Pharmaceuticals, INC. | $182.67 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.80 | 2019-2023 | Jardiance, Stiolto Respimat |
| Lilly USA, LLC | $136.09 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Corium, LLC | $134.28 | 2023 | Azstarys |
| Exact Sciences Corporation | $120.37 | 2023-2025 | Cologuard Collection Kit |
| Myriad Women'S Health, INC. | $107.08 | 2023 | Myrisk |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.76 | 2021-2023 | Xifaxan |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $86.52 | 2021-2022 | |
| Astellas Pharma US INC | $64.71 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $48.40 | 2022-2024 | Eliquis |
| Amneal Pharmaceuticals LLC | $44.81 | 2022-2025 | Unithroid |
| Sanofi Pasteur INC. | $32.66 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $30.25 | 2021-2025 | Zoryve |
| Medtronic, INC. | $28.76 | 2022-2023 | Intellis Adaptivestim |
| Nevro Corp. | $25.28 | 2024 | Senza |
| Amarin Pharma, INC. | $24.91 | 2020 | |
| Dynavax Technologies Corporation | $24.89 | 2023 | Heplisav-B |
| Otsuka America Pharmaceutical, INC. | $19.74 | 2024 | Rexulti |
| Abbott Laboratories | $18.60 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.08 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.05 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $15.43 | 2024 | Xarelto |
| Allergan, INC. | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Grube listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.